These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 34021647)
1. A novel mouse model for liver metastasis of prostate cancer reveals dynamic tumour-immune cell communication. Liu K; Jing N; Wang D; Xu P; Wang J; Chen X; Cheng C; Xin Z; He Y; Zhao H; Ji Z; Zhang P; Gao WQ; Zhu HH; Zhang K Cell Prolif; 2021 Jul; 54(7):e13056. PubMed ID: 34021647 [TBL] [Abstract][Full Text] [Related]
2. Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells. Barakat DJ; Suresh R; Barberi T; Pienta KJ; Simons BW; Friedman AD PLoS One; 2018; 13(1):e0191188. PubMed ID: 29324844 [TBL] [Abstract][Full Text] [Related]
3. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer. Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391 [TBL] [Abstract][Full Text] [Related]
4. Extracellular Vesicles from Luo ZW; Xia K; Liu YW; Liu JH; Rao SS; Hu XK; Chen CY; Xu R; Wang ZX; Xie H Int J Nanomedicine; 2021; 16():2949-2963. PubMed ID: 33907401 [TBL] [Abstract][Full Text] [Related]
5. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal. Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780 [TBL] [Abstract][Full Text] [Related]
6. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628 [TBL] [Abstract][Full Text] [Related]
7. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model. van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757 [TBL] [Abstract][Full Text] [Related]
8. Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN Pan H; Lu LY; Wang XQ; Li BX; Kelly K; Lin HS Chin J Integr Med; 2018 Feb; 24(2):109-116. PubMed ID: 28578487 [TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
10. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754 [TBL] [Abstract][Full Text] [Related]
11. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer. Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438 [TBL] [Abstract][Full Text] [Related]
12. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. Fujimori D; Kinoshita J; Yamaguchi T; Nakamura Y; Gunjigake K; Ohama T; Sato K; Yamamoto M; Tsukamoto T; Nomura S; Ohta T; Fushida S BMC Cancer; 2020 Oct; 20(1):1014. PubMed ID: 33081727 [TBL] [Abstract][Full Text] [Related]
13. Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer. Alioui A; Dufour J; Leoni V; Loregger A; Moeton M; Iuliano L; Zerbinati C; Septier A; Val P; Fouache A; Russo V; Volle DH; Lobaccaro JA; Zelcer N; Baron S Nat Commun; 2017 Sep; 8(1):445. PubMed ID: 28874658 [TBL] [Abstract][Full Text] [Related]
14. The immune influence of a parabiosis model on tumour-bearing mice. Feng N; Luo JM; Guo X Swiss Med Wkly; 2018 Sep; 148():w14678. PubMed ID: 30294773 [TBL] [Abstract][Full Text] [Related]
15. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033 [TBL] [Abstract][Full Text] [Related]
16. Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Zhou P; Fang X; McNally BA; Yu P; Zhu M; Fu YX; Wang L; Liu Y; Zheng P Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17134-9. PubMed ID: 19805094 [TBL] [Abstract][Full Text] [Related]
17. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425 [TBL] [Abstract][Full Text] [Related]